AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2016

Summary

Amgen Inc. reported strong financial results for the first quarter of 2016, with total revenues increasing by 10% to $5.53 billion and net income growing by 17% to $1.90 billion. Diluted earnings per share (EPS) also saw a significant increase of 18% to $2.50. This growth was driven by a 7% increase in product sales, reaching $5.24 billion, with key products like Enbrel, Prolia, and Aranesp showing robust performance. The company also benefited from an 81% surge in other revenues, largely due to an upfront partner payment and increased royalty income. Despite a 4% increase in operating expenses, the company's operating income grew by 19%, demonstrating effective cost management and revenue expansion. Amgen continued its commitment to returning capital to shareholders, declaring a quarterly dividend and actively engaging in stock repurchases.

Key Highlights

• 1Total revenues increased 10% year-over-year to $5.53 billion.
• 2Net income rose 17% to $1.90 billion, with diluted EPS growing 18% to $2.50.
• 3Product sales increased 7% to $5.24 billion, driven by strong performance in key therapeutic areas and products like Enbrel, Prolia, and Aranesp.
• 4Other revenues saw a significant jump of 81% to $288 million, primarily due to a license agreement upfront payment and higher royalty income.
• 5Operating income increased by 19% to $2.40 billion, indicating improved operational efficiency.
• 6The company declared a quarterly dividend of $1.00 per share and repurchased $690 million of its stock in the quarter, signaling confidence in future cash flows.
• 7Significant progress was made in the development of romosozumab, with two Phase 3 studies meeting their primary endpoints.

Frequently Asked Questions